Agreement - January 5, 2023
Alligator and Orion initiate second immuno-oncology program
Alligator Bioscience has announced an expansion to its research collaboration and license agreement with Orion Corporation, to discover and develop together new bispecific antibody cancer therapeutics. The collaboration has been expanded to add the development of a second bispecific antibody using Alligator’s bispecific RUBY platform, where Alligator will provide validated monospecific binders for one target […]
Agreement - January 4, 2023
Orion and Amneal enter strategic partnership
Orion Corporation has signed a long-term license agreement with Amneal Pharmaceuticals to commercialize Amneal’s generic products in Orion territories. Under the terms of the agreement, Orion is granted exclusive licence to commercialize and sell Amneal’s generic products in most parts of Europe as well as in Australia and New Zealand. The initial portfolio will include […]
Biotech Business - December 21, 2022
Anocca secures 25 million EUR
Swedish Anocca has secured Venture Debt financing from the European Investment Bank (EIB). This significant investment recognizes the strength and high potential of Anocca and its transformational approach to developing T-cell therapies for cancer, the company states. “This financing supports us in moving our first generation of T-cell immunotherapies towards clinical trials in a solid […]
Pharma Business - December 21, 2022
AstraZeneca’s Enhertu approved in the EU
AstraZeneca and Daiichi Sankyo’s Enhertu has been approved in the European Union as monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. Enhertu is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialized by AstraZeneca and Daiichi […]
Acquisition - December 12, 2022
SynAct acquires TXP Pharma and carries out a directed share issue
SynAct Pharma has entered into a conditional agreement on acquisition of TXP Pharma, a Swiss-incorporated biotech company researching and developing pharmaceutical drugs for the treatment of autoimmune and inflammatory diseases. The purchase price consists of a fixed purchase price of SEK 136 million and a potential additional purchase price of SEK 55 million, where the […]
Biotech Business - December 8, 2022
Oncopeptides provides update on US marketing authorization
Oncopeptides has announced that the US Food and Drug Administration, FDA, has requested a withdrawal of the US marketing authorization for Pepaxto. The request is based on the outcome of the confirmatory phase 3 OCEAN study, which demonstrated an ITT overall survival HR of 1.1, but with significant survival result differences for both melflufen and […]
